Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 16;16:204–217. doi: 10.1016/j.bioactmat.2022.02.013

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Fig. 5 — Therapeutic effect of tumor-derived sEVs as DOX carriers for GBM suppression. (A) U251 viability after 24 h incubation with free DOX or sa-U251-sEVs-DOX. (B) Flow cytometry analysis of the apoptosis of U251 cells after treatment with free DOX or sa-U251-sEV-DOX for 24 h. Cell apoptosis was detected by Annexin V/PI as a maker. (C) Statistical analysis of the apoptosis rate. (D) Images of the extracted subcutaneous xenograft tumor treated with PBS, free DOX, or sa-U251-sEVs-DOX 7 d after treatments. The DOX or sa-U251-sEVs-DOX was administrated on the 7th day after U251 injection. (E) Tumor weight analysis. (F) Tumor volume analysis. **P < 0.01, ***P < 0.001.